{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:11:11Z","timestamp":1779923471031,"version":"3.53.1"},"reference-count":31,"publisher":"PeerJ","license":[{"start":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T00:00:00Z","timestamp":1615852800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007632","name":"Changhua Christian Hospital","doi-asserted-by":"crossref","award":["108-CCH-IRP-018"],"award-info":[{"award-number":["108-CCH-IRP-018"]}],"id":[{"id":"10.13039\/501100007632","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007632","name":"Changhua Christian Hospital","doi-asserted-by":"crossref","award":["109-CCH-IRP-008"],"award-info":[{"award-number":["109-CCH-IRP-008"]}],"id":[{"id":"10.13039\/501100007632","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n               <jats:title>Introduction<\/jats:title>\n               <jats:p>Chronic hepatitis C virus (HCV) infection rates are high in the geriatric population considering that interferon-based therapy is usually intolerable. With the introduction of oral antiviral therapy for HCV, increased treatment tolerability and good treatment responses have been observed. However, treatment data regarding the geriatric population have been limited. Therefore, this retrospective study aimed to evaluate the efficacy and safety of direct-acting antiviral therapy for HCV in the geriatric population.<\/jats:p>\n            <\/jats:sec>\n            <jats:sec>\n               <jats:title>Materials and Methods<\/jats:title>\n               <jats:p>The primary end point was sustained virologic response (SVR) 12 weeks after treatment completion, whereas the secondary end points were treatment-related side effects and short-term survival rate following treatment.<\/jats:p>\n            <\/jats:sec>\n            <jats:sec>\n               <jats:title>Results<\/jats:title>\n               <jats:p>In total, 492 patients (median age, 73 years; 43.9% males), including 278 early elderly patients, were enrolled. Among the included patients, 45% had cirrhosis. HCV genotypes 1 (72.4%) and 2 (25.4%) were the most common. The overall SVR rate was 96.7%, with no difference in SVR rates observed between early and late elderly groups (96.8% vs. 96.7%; <jats:italic>p<\/jats:italic>\u00a0=\u00a00.983). Both groups showed similar side effects, including dizziness (11.4%), and fatigue (8.7%), with three patients discontinuing therapy owing to side effects. Both groups had a similar 3-year survival rate. Significant factors associated with post-treatment survival included cirrhosis, albumin, and creatinine level.<\/jats:p>\n            <\/jats:sec>\n            <jats:sec>\n               <jats:title>Conclusions<\/jats:title>\n               <jats:p>Our real-world data showed that both early and late elderly patients could undergo direct-acting antiviral treatment for HCV with excellent treatment outcomes.<\/jats:p>\n            <\/jats:sec>","DOI":"10.7717\/peerj.10944","type":"journal-article","created":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T12:06:17Z","timestamp":1615896377000},"page":"e10944","source":"Crossref","is-referenced-by-count":10,"title":["Direct-acting antiviral treatment for Hepatitis C Virus in geriatric patients: a real-world retrospective comparison between early and late elderly patients"],"prefix":"10.7717","volume":"9","author":[{"given":"Hsu-Heng","family":"Yen","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan"},{"name":"General Educational Center, Chienkuo Technology University, Changhua, Taiwan"},{"name":"Institute of Medicine, Chung Shan Medical and Dental College, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Yuan","family":"Su","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Ling","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Yuei","family":"Zeng","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siou-Ping","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chun","family":"Hsu","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Wei","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang-Yuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4443","published-online":{"date-parts":[[2021,3,16]]},"reference":[{"key":"10.7717\/peerj.10944\/ref-1","doi-asserted-by":"publisher","first-page":"9633","DOI":"10.3748\/wjg.v20.i29.9633","article-title":"Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy","volume":"20","author":"Ansaldi","year":"2014","journal-title":"World Journal of Gastroenterology"},{"key":"10.7717\/peerj.10944\/ref-2","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.2147\/CIA.S107750","article-title":"European society for swallowing disorders\u2014European Union Geriatric Medicine Society white paper: oropharyngeal dysphagia as a geriatric syndrome","volume":"11","author":"Baijens","year":"2016","journal-title":"Clinical Interventions in Aging"},{"key":"10.7717\/peerj.10944\/ref-3","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S1473-3099(19)30073-8","article-title":"Eliminating hepatitis C","volume":"19","author":"Burki","year":"2019","journal-title":"The Lancet Infectious Diseases"},{"key":"10.7717\/peerj.10944\/ref-4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2165\/00002512-200825010-00002","article-title":"Hepatitis C virus infection in the elderly: epidemiology, natural history and management","volume":"25","author":"Cainelli","year":"2008","journal-title":"Drugs Aging"},{"key":"10.7717\/peerj.10944\/ref-5","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.12998\/wjcc.v7.i11.1270","article-title":"Anti-hepatitis C virus therapy in chronic kidney disease patients improves long-term renal and patient survivals","volume":"7","author":"Chen","year":"2019","journal-title":"World Journal of Clinical Cases"},{"key":"10.7717\/peerj.10944\/ref-6","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/jvh.13305","article-title":"Real-world effectiveness of glecaprevir\/pibrentasvir and ledipasvir\/sofosbuvir for mixed genotype hepatitis C infection: a multicenter pooled analysis in Taiwan","volume":"27","author":"Chiu","year":"2020","journal-title":"The Journal of Viral Hepatitis"},{"key":"10.7717\/peerj.10944\/ref-7","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1111\/liv.13339","article-title":"Direct-acting antivirals combination for elderly patients with chronic hepatitis C: a cost-effectiveness analysis","volume":"37","author":"Ciaccio","year":"2017","journal-title":"Liver International"},{"key":"10.7717\/peerj.10944\/ref-8","first-page":"227","article-title":"Pruritus in the elderly: clinical approaches to the improvement of quality of life","volume":"37","author":"Cohen","year":"2012","journal-title":"P T"},{"key":"10.7717\/peerj.10944\/ref-9","doi-asserted-by":"publisher","first-page":"e0208506","DOI":"10.1371\/journal.pone.0208506","article-title":"Safety and efficacy of glecaprevir\/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older","volume":"14","author":"Foster","year":"2019","journal-title":"PLOS ONE"},{"key":"10.7717\/peerj.10944\/ref-10","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/hepr.12279","article-title":"Long-term outcome of elderly patients (75 years or older) with hepatocellular carcinoma","volume":"44","author":"Hori","year":"2014","journal-title":"Hepatology Research"},{"key":"10.7717\/peerj.10944\/ref-11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/apt.12112","article-title":"Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C","volume":"37","author":"Hu","year":"2013","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"11","key":"10.7717\/peerj.10944\/ref-12","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1002\/kjm2.12275","article-title":"Cure or curd: modification of lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication","volume":"36","author":"Huang","year":"2020","journal-title":"The Kaohsiung Journal of Medical Sciences"},{"key":"10.7717\/peerj.10944\/ref-13","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.14309\/ajg.0000000000000606","article-title":"Extrahepatic malignancy among patients with chronic hepatitis c after antiviral therapy: a real-world nationwide study on taiwanese chronic hepatitis C Cohort (T-COACH)","volume":"115","author":"Huang","year":"2020","journal-title":"American Journal of Gastroenterology"},{"key":"10.7717\/peerj.10944\/ref-14","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1080\/14656566.2017.1400010","article-title":"Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments","volume":"18","author":"Huang","year":"2017","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.7717\/peerj.10944\/ref-15","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-020-06286-3","article-title":"Excellent safety and sustained virologic response to direct-acting antivirals treatment in HCV-infected geriatric patients: a real-world data","author":"Huynh","year":"2020","journal-title":"Digestive Diseases and Sciences"},{"key":"10.7717\/peerj.10944\/ref-16","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/S2468-1253(19)30227-4","article-title":"Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study","volume":"4","author":"Lee","year":"2019","journal-title":"The Lancet Gastroenterology and Hepatology"},{"key":"10.7717\/peerj.10944\/ref-17","doi-asserted-by":"publisher","first-page":"729","DOI":"10.7326\/0003-4819-159-11-201312030-00005","article-title":"Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial","volume":"159","author":"Liu","year":"2013","journal-title":"Annals of Internal Medicine"},{"key":"10.7717\/peerj.10944\/ref-18","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/jvh.13265","article-title":"Glecaprevir\/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment","volume":"27","author":"Liu","year":"2020","journal-title":"The Journal of Viral Hepatitis"},{"key":"10.7717\/peerj.10944\/ref-19","doi-asserted-by":"publisher","first-page":"122","DOI":"10.6501\/cjm.202012_18(4).0002","article-title":"Interferon-free anti-HCV therapy has a better treatment response rate and adherence than interferon-based therapy for patients with HCV\/HIV coinfection: a single-center retrospective study","volume":"18","author":"Liu","year":"2020","journal-title":"The Changhua Journal of Medicine"},{"key":"10.7717\/peerj.10944\/ref-20","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s40121-016-0134-x","article-title":"Value of treating all stages of chronic hepatitis C: a comprehensive review of clinical and economic evidence","volume":"5","author":"Nuno Solinis","year":"2016","journal-title":"Infectious Diseases and Therapy"},{"key":"10.7717\/peerj.10944\/ref-21","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1080\/14787210.2017.1354697","article-title":"Extrahepatic manifestations of HCV: the role of direct acting antivirals","volume":"15","author":"Polo","year":"2017","journal-title":"Expert Review of Anti-infective Therapy"},{"key":"10.7717\/peerj.10944\/ref-22","doi-asserted-by":"publisher","first-page":"10984","DOI":"10.3748\/wjg.v20.i31.10984","article-title":"Age-related differences in response to peginterferon alfa-2a\/ribavirin in patients with chronic hepatitis C infection","volume":"20","author":"Roeder","year":"2014","journal-title":"World Journal of Gastroenterology"},{"key":"10.7717\/peerj.10944\/ref-23","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/hep.28425","article-title":"Safety and efficacy of ledipasvir\/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older","volume":"63","author":"Saab","year":"2016","journal-title":"Hepatology"},{"key":"10.7717\/peerj.10944\/ref-24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3851\/IMP2975","article-title":"Hepatitis C cure with antiviral therapy\u2013benefits beyond the liver","volume":"21","author":"Soriano","year":"2016","journal-title":"Antiviral Therapy"},{"key":"10.7717\/peerj.10944\/ref-25","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1111\/jvh.13169","article-title":"Direct-acting antivirals for HCV treatment in older patients: A systematic review and meta-analysis","volume":"26","author":"Villani","year":"2019","journal-title":"Journal of Viral Hepatitis"},{"key":"10.7717\/peerj.10944\/ref-26","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.ijantimicag.2019.07.005","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir for chronic hepatitis C virus genotypes 1-6 infection: a systematic review and meta-analysis","volume":"54","author":"Wang","year":"2019","journal-title":"International Journal of Antimicrobial Agents"},{"key":"10.7717\/peerj.10944\/ref-27","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1007\/s12325-019-01012-6","article-title":"Assessing patient preferences for treatment decisions for new direct acting antiviral (DAA) therapies for chronic hepatitis C virus infections","volume":"36","author":"Welzel","year":"2019","journal-title":"Advances in Therapy"},{"key":"10.7717\/peerj.10944\/ref-28","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.jfma.2018.10.021","article-title":"Achieving hepatitis C elimination in Taiwan-Overcoming barriers by setting feasible strategies","volume":"117","author":"Wu","year":"2018","journal-title":"Journal of the Formosan Medical Association"},{"key":"10.7717\/peerj.10944\/ref-29","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.atherosclerosis.2018.01.007","article-title":"Comparison of cardiovascular outcomes and all-cause mortality in patients with chronic hepatitis B and C: a 13-year nationwide population-based study in Asia","volume":"269","author":"Wu","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.7717\/peerj.10944\/ref-30","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.3748\/wjg.v18.i36.5084","article-title":"Decreased mitochondrial deoxyribonucleic acid and increased oxidative damage in chronic hepatitis C","volume":"18","author":"Yen","year":"2012","journal-title":"World Journal of Gastroenterology"},{"key":"10.7717\/peerj.10944\/ref-31","doi-asserted-by":"publisher","first-page":"e0237582","DOI":"10.1371\/journal.pone.0237582","article-title":"Glecaprevir-pibrentasvir for chronic hepatitis C: comparing treatment effect in patients with and without end-stage renal disease in a real-world setting","volume":"15","author":"Yen","year":"2020","journal-title":"PLOS ONE"}],"container-title":["PeerJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/peerj.com\/articles\/10944.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/10944.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/10944.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/10944.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T12:06:22Z","timestamp":1615896382000},"score":1,"resource":{"primary":{"URL":"https:\/\/peerj.com\/articles\/10944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,16]]},"references-count":31,"alternative-id":["10.7717\/peerj.10944"],"URL":"https:\/\/doi.org\/10.7717\/peerj.10944","archive":["CLOCKSS","LOCKSS","Portico"],"relation":{},"ISSN":["2167-8359"],"issn-type":[{"value":"2167-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,16]]},"article-number":"e10944"}}